References
- World Health Organization. Dengue and severe dengue. Geneva (Switzerland). 2016. [ accessed 2017 Apr 14]. http://www.who.int/mediacentre/factsheets/fs117/en/.
- Editorial: dengue–an infectious disease of staggering proportions. Lancet. 2013;381(9884):2136. doi:10.1016/S0140-6736(13)61423-3.
- Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15(12):745–759. doi:10.1038/nri3916.
- World Health Organization. Revised SAGE recommendation on use of dengue vaccine – 19 April 2018. Weekly Epidemiologic Rec. No 23, 2018 Jun 8, 93, 337–340. [ accessed 2017 Jun 14]. http://apps.who.int/iris/bitstream/handle/10665/272782/WER9323.pdf?ua=1
- Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, et al. Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine. 2015;33(50):7126–7134. doi:10.1016/j.vaccine.2015.09.101.
- Harris JR, Soliakov A, Lewis RJ, Depoix F, Watkinson A, Lakey JH. Alhydrogel® adjuvant, ultrasonic dispersion and protein binding: a TEM and analytical study. Micron. 2012;43(2–3):192–200. doi:10.1016/j.micron.2011.07.012.
- Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol. 2012;61(Pt 7):935–943. doi:10.1099/jmm.0.040857-0.
- Govindarajan D, Meschino S, Guan L, Clements DE, Ter Meulen JH, Casimiro DR, Coller BA, Bett AJ. Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine. 2015 Aug 7;33(33):4105–4116. doi:10.1016/j.vaccine.2015.06.067.
- Lindblad EB. Aluminium adjuvants–in retrospect and prospect. Vaccine. 2004;22(27–28):3658–3668. doi:10.1016/j.vaccine.2004.03.032.
- Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine. 2010; 28(15): 2705–2715. doi:10.1016/j.vaccine.2010.01.022.
- McKenzie A, Watt M, Gittleson C. ISCOMATRIX vaccines: safety in human clinical studies. Hum Vaccin. 2010;6(3):pii: 10754. PMID: 20595811.
- Bigaeva E, Doorn EV, Liu H, Hak E. Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: safety and tolerability. PLoS One. 2016;11(5):e0154757. doi:10.1371/journal.pone.0154757.
- World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. 2009. Geneva (Switzerland). [ accessed 2018 Jun 14]. http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf.
- Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4(4):e4991. doi:10.1371/journal.pone.0004991.
- Coller BAG, Durbin A, Kirkpatrick B, Pierce K, Grier P, Sabundayo B, Larsson C, He H, Sausser M, Russell A, et al. A phase I clinical trial evaluating the impact of tetravalent recombinant subunit dengue vaccine boost administered to subjects who have previously been vaccinated with a live-attenuated tetravalent dengue vaccine. Presented at the 2016 Annual Meeting of the American Society of Tropical Medicine and Hygiene, Abstract #59; http://www.astmh.org/ASTMH/media/Documents/Abstracts-1-500-ASTMH-2016-Annual-Meeting-Abstract-Book.pdf.
- World Health Organization. Guidelines for plaque reduction neutralizing testing of human antibodies to dengue viruses. Geneva (Switzerland). 2007. [ accessed 2018 Jun 14]. http://apps.who.int/iris/bitstream/handle/10665/69687/who_ivb_07.07_eng.pdf;jsessionid=026253819A4C9E43950ADDF81F87A8B8?sequence=1.
- Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008;21:123–132. doi:10.1089/vim.2008.0007.
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Sept 2007. [ accessed 2018 Apr 14]. https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.